$1m Grant to Fund Phase Study—Testing Novel Immunotherapy Targeting FLT3 Receptor Protein at CHOP
755
0 comment
The Pediatric Cancer Foundation Pediatric Cancer Foundation gave $1 million to the Children’s Hospital of Philadelphia (CHOP) to help the prominent hospital and trial site fund a planned first-in-human phase 1 clinical trial led by Sarah K. Tasian, M.D., involving a novel investigational immunotherapy to target the FLT3 receptor protein in high-risk pediatric leukemias.
What’s the health challenge?
Quality journalism costs money to produce.
Free access provides up to 10 articles
Subscription options start at $5 per month
which is less than a Starbucks coffee!
Peter Gabriel, MD
"Publishing on TrialSite helped me secure a $20m research grant for my work."
Jona Savinda
"TrialSiteNews is my daily read for what is happening in the industry."
Lucas Van Der Hoven
"Objective, unbiased reporting on the latest news in medical research. I trust TrialSiteNews to give it to me straight."
Publish on TrialSite
TrialSiteNews
159 W Broadway, Suite 200
Salt Lake City, UT 84101
© 2025 - Trial Site News